Gapping up
In reaction to strong earnings/guidance:
- DCT +12.1%, JMEI +10.5%, FDC +7.7%, WPP +7.2%, CRON +4.4%, MPLX +3.4%, KMPR +2.9%, AGN +2.4%, EPD +2%, MOH +1.6%, L +1.1%, CUBI +1.1%, ARLP +0.9%, BWP +0.5%
M&A news:
- STDY +77.4% (UTHR to acquire SteadyMed (STDY) for $4.46/share in cash at closing)
- ANDV +16.8% (to be acquired by Marathon Petroleum (MPC) in a $23.3 bln deal)
- DCT +12.1% (to be acquired by Prologis (PLD) for $8.4 bln in a stock-for-stock transaction)
- ILG +5.4% (to be acquired by Marriott Vacations Worldwide (VAC) for approximately $4.7 bln in cash/stock)
- BIDU +0.7% (to divest its financial service business)
Other news:
- PSTI +12.9% (FDA has cleared the IND application for its PLX-R18 cell therapy in the treatment of acute radiation syndrome)
- AMZN +0.6% (slightly rebounding in pre-mkt)
Analyst comments:
- SAVE +3.6% (upgraded to Overweight at JP Morgan)
- WETF +3.3% (upgraded to Outperform from Mkt Perform at Keefe Bruyette)
- TTWO +2.4% (upgraded to Outperform from Neutral at Wedbush)
- SPOT +2% (initiated with a Buy at Goldman; initiated with a Overweight at JP Morgan)
- MO +1.1% (upgraded to Outperform from Sector Perform at RBC Capital Mkts)
- VTR +0.8% (upgraded to Market Perform from Underperform at BMO Capital Markets)
- WFC +0.6% (upgraded to Outperform from Neutral at Macquarie)
![]()